Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 28 ... in Phase I studies, supports the potential of FV-100 as a highly potent, once-daily oral therapy to reduce the incidence and severity of shingles-related symptoms, including ... worldwide are infected with HCV. HCV can cause chronic liver disease, cirrhosis and cancer, and is the leading cause of liver transplant in the United States.Inhibitex ...
2009 NOV 23 ... and use of multiplanar reformations (MPRs) for abdomen and pelvis. The use of neutral oral contrast material and proper timing of intravenous contrast agent with fast scanning is ... chest CT, the diagnosis of pulmonary artery and aortic abnormalities, lung cancer and the solitary nodule, and use of multiplanar reformations (MPRs) for abdomen and ...
2009 NOV 23 ... synthesis, which leads to imbalanced cell growth and ultimately cell death. 5-FU and its oral prodrug capecitabine are used in the treatment of a number of solid tumors, including ... Shahrokni and colleagues published their study in Clinical Colorectal Cancer (Toxicity and Efficacy of 5-Fluorouracil and Capecitabine in a Patient With TYMS Gene ...
2009 NOV 23 ... injection of natural IFN-alpha at 3 x 106 or 5 x 106 U three times weekly plus oral administration of meloxicam at 10 mg once daily. A total of 43 patients were enrolled in ... Meloxicam, Nephrectomy, Nephrology, Oncology, Pain Medicine, Pharmaceuticals, Renal Cell Cancer, Renal Cell Carcinoma, Solid Cancers, Solid Carcinomas, Surgery, Treatment. ...
2009 NOV 23 ... Nakamori and colleagues published their study in International Journal of Oral and Maxillofacial Surgery (Carcinoma ex pleomorphic adenoma of the buccal region is ... Endocrinology, Maxillofacial Surgery, Oncology, Otorhinolaryngology, Salivary Gland Cancer, Salivary Gland Carcinoma, Squamous Cell Carcinoma. This article was ...
2009 NOV 29 ... p53 is present. (Neuroblastoma is a childhood tumor that often has a poor outcome). Oral administration of nutlin-3 as a single agent reduced tumor growth and ... according to a new study published online November 10 in the Journal of the National Cancer Institute.In this study in mice, Tom Van Maerken, M.D., Center for Medical ...
2009 NOV 23 ... Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development ... growth of Onyx, and positions the company to bring multiple, new treatment options to cancer patients," said Todd Yancey, vice president clinical development at Onyx. "Despite ...
2009 NOV 23 ... For additional information, contact L. Liu, Sichuan University, State Key Laboratory Oral Diseases, W China Hospital Stomatol, Chengdu 610041, People's Republic of China. ... are important posttranscriptional regulation of genes. A link between miRNA function and cancer was researched by the miRNAs microarray technology recently." "Howerver, ...
2009 NOV 23 ... effects. Hence, studies of FICZ were also carried out in MSK-Leuk1 cells, a model of oral leukoplakia. Pretreatment with alpha-naphthoflavone or 17-AAG blocked FICZ-mediated ... Nair and colleagues published the results of their research in Cancer Prevention Research (UVR Exposure Sensitizes Keratinocytes to DNA Adduct Formation. ...
2009 NOV 23 ... was provided trichloroacetic acid (TCA) as 0.5 g/kg/day for five consecutive days by oral gavage. Animals were killed before tumor development. The treatment revealed dysplastic ... membrane integrity. Down-regulation of HP, TSA, and TGAGs seems to be a prerequisite for cancer development. This might be stimulated by up-regulation of free cathepsin D activity. ...
2009 NOV 23 ... Han and colleagues published their study in International Journal of Oral and Maxillofacial Surgery (Bilateral chylothorax following neck dissection for thyroid ... neck dissection and superior mediastinal dissection for bilateral medullary thyroid cancer. The patient was treated successfully with conservative management," wrote C. Han and ...
2009 NOV 23 ... The researchers concluded: "Furthermore, similar durations of tube feeding, days to oral feeding, and hospitalization period were recorded in both groups. onclusion: The PMMF ... total laryngectomy. Retrospective cohort analysis." "Tertiary care cancer center. The study included 461 patients who underwent laryngectomy. Eighty of them ...
2009 NOV 23 ... commencement of treatment and its relation to therapeutic variables in patients with oral and oropharyngeal carcinoma. QoL was assessed using the EORTC QLQ-C30 questionnaires and ... QoL was assessed using the EORTC QLQ-C30 questionnaires and the EORTC head and neck cancer specific module QLQ-H&N35." "QoL data were obtained prior to treatment ...
2009 NOV 23 ... Melchers and colleagues published their study in International Journal of Oral and Maxillofacial Surgery (Exercise adherence in patients with trismus due to head and ... from Netherlands, "Trismus is a common problem after treatment of head and neck cancer. The Therabite ® is an effective treatment for trismus." "To explore ...
2009 NOV 23 ... University. The researchers concluded: "Management of LRPLN metastasis in oral cancer patients is a challenge for oral surgeons, but early detection by CT or MRI and surgery ...
2009 NOV 23 ... mechanisms that allow CRPC tumors to grow. About TOK-001 TOK-001 is a small molecule, oral drug that disrupts the growth and survival of cancer cells by attacking three specific ...
2009 NOV 23 ... may also work in treating other cancers. This is particularly interesting if the oral form is successful in the clinic," added Lawrence Einhorn, MD, Distinguished Professor ... of the Center for Sarcoma and Bone Oncology and the Ludwig Center at the Dana-Farber Cancer Institute and Harvard Medical School, and a member of ZIOPHARM's Medical Advisory ...
2009 NOV 23 ... trial in peripheral T-cell lymphoma, also as early as the first half of 2010. The oral darinaparsin Phase I trials continue enrollment in order to establish the best dose and ... seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, reported its financial results for the quarter ...
